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ABSTRACT Chronic infection and inflammation are defining characteristics of cystic fibrosis (CF) airway
disease. Conditions within the airways of patients living with CF are conducive to colonisation by a variety
of opportunistic bacterial, viral and fungal pathogens. Improved molecular identification of microorgan-
isms has begun to emphasise the polymicrobial nature of infections in the CF airway microenvironment.
Changes to CF airway physiology through loss of cystic fibrosis transmembrane conductance regulator
functionality result in a wide range of immune dysfunctions, which permit pathogen colonisation and
persistence. This review will summarise the current understanding of how CF pathogens infect, interact with
and evade the CF host.
@ERSpublications
Current understanding of how cystic fibrosis pathogens infect, interact with and evade the cystic
fibrosis host http://ow.ly/tAM9m
Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder arising from functional deficiency of the cystic
fibrosis transmembrane conductance regulator (CFTR). Although this channel is primarily responsible for
facilitating conductance of chloride ions across membranes, it also transports other molecules including
bicarbonate [1, 2], glutathione [3, 4], and thiocyanate [5]. The loss of CFTR function has wide-ranging
effects on human health, with disease manifestation in the pancreas, liver, gastrointestinal tract and lungs, as
well as in the male reproductive tract. Lung disease is responsible for the majority of morbidity and death in
CF and is the largest obstacle in therapy. CF lung disease is characterised by high levels of infiltrating cells
(especially neutrophils, but also lymphocytes and macrophages [6]), elevated levels of inflammatory
cytokines [7, 8], and chronic colonisation by opportunistic pathogens [9]. These microorganisms exploit
niches in the CF lung environment to elicit sustained inflammatory responses, resulting in significant
structural damage to the airways and decline of pulmonary function [10]. Understanding how
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microorganisms colonise and persist in the lung environment while subverting the host immune response is a
critical step in developing specifically targeted anti-inflammatories that can be used in conjunction with
antibiotic and airway clearance therapies. Loss of CFTR can be understood to affect host–pathogen interactions
through several key functions: alteration of the lung microenvironment and permissibility of infection,
endogenous dysregulation of host defence mechanisms, and by directly affecting pathogen recognition.
The CF lung microenvironment
The mechanism through which the loss of Cl- secretion through the CFTR results in the decline of the
mucus and periciliary layer volumes of the airway surface liquid (ASL) is still unclear [11]. One of the
leading hypotheses argues that the CFTR may serve to regulate Na+ and, consequently, water reabsorption
by epithelial Na+ channels (ENaC) expressed on the airway epithelium. This has been supported by studies
showing that overexpression of ENaC results in airway disease that is characteristic of CF in mice [12] and
various cellular models showing that ENaC expression and function is regulated by CFTR [13, 14]. This has
been contested in studies that have found that Na+ conductance is unaffected in CF airway epithelia of pigs
[15] and humans [16] and that the CF disease phenotype may more strictly reflect a loss of Cl- secretion.
However, this does not discount ENaC as a potentially effective therapeutic target [17].
CF airway disease is manifested through decreased ASL volume, increased mucus viscosity, and impaired
mucus elimination by ciliated cells, thereby crippling a primary mechanism of defence in the airways and
creating a more static environment for microbial growth. Both infectious [18] and noninfectious stimuli,
including interleukin (IL)-1b, IL-17 [19] and neutrophil elastase (NE) [20], drive mucin 5AC (MUC5AC)
synthesis [21] that could contribute to mucus accumulation. MUC5AC is important in preventing bacterial
adherence in the lung [22] and hypersecretion of MUC5AC alone does not seem to cause respiratory disease
[23]. However, in disease states like CF mucin structure, expansion and function may be affected by altered
pH [24, 25]. DNA, which is abundant in CF sputum [26], further contributes to mucus viscosity, but may
be treated with some success using recombinant DNase I [27, 28].
The sputum of CF patients itself is also conducive to microbial growth as it is quite nutrient rich. Amino
acids are found in increased amounts in the sputum of CF patients when compared with healthy controls
[29] and correlate with disease severity [30]. Iron, which is sequestered by transferrin, lactoferrin and
ferritin, can be found in high amounts in sputum [31, 32], bronchoalveolar lavage fluid (BALF) and lung
tissue of the lower airways in CF [33]. Here it can be exploited as an essential cofactor for bacterial enzymes
and may also promote biofilm formation [34]. Sputum iron levels were found to correlate positively with
the inflammatory cytokines, IL-1b and tumour necrosis factor (TNF)-a and ferritin, but negatively with
lung function as measured by forced expiratory volume in 1 s (FEV1). Increases were detected in both stable
and acute disease in a sample population that was largely sputum culture positive for Pseudomonas
aeruginosa [31]. This increase in iron was observed even in patients who were culture negative for
P. aeruginosa, indicating that CF lungs may be more susceptible to infection. In P. aeruginosa positive
patients, iron levels correlated positively with bacterial load [32]. Ultimately, these nutrient and iron rich
conditions are conducive to microbial growth and may support chronic infection [32, 35]. Mucus in regions
of the CF airways has been found to be hypoxic or anaerobic, likely due to increased local aerobic
respiration by colonising microbes [9, 36] but also by increased generation of reactive oxygen species by
neutrophils [37]. Some microorganisms, such as P. aeruginosa, are capable of efficient growth in anaerobic
conditions, but also grow under oxygen-limited microaerobic conditions and anaerobic conditions where
denitrification is employed to reduce available nitrate, nitrite and nitrous oxide molecules to nitrogen.
Microaerobic or anaerobic growth allows P. aeruginosa to access an additional environmental niche and
may also confer the benefit of increased resistance to antibiotics [38] through manipulation of MexEF-
OprN efflux pump expression [39].
Secreted host defence molecules augment mucus clearance as a key barrier to microbial survival within the
lung. These include a variety of antimicrobials in the ASL, as well as the recruitment of cellular effectors to
the site of infection. However, changes to CF airway homeostasis impair these defences, which may be
attributed to alterations in pH, protein oxidation, and protease activity. This is illustrated in the pig CF
model in which pigs lacking CFTR or expressing DF508-CFTR developed lung disease similar to CF in
humans [40] and were diminished in their ability to eliminate bacteria [41]. Bacterial killing is reduced in
the ASL of CF pigs when compared with controls despite both groups possessing similar concentrations of
antimicrobials [42]. This defect in bacterial killing is attributed to a lowered ASL pH, resulting in impaired
function of antimicrobials including lactoferrin and lysozyme [43]. b-defensin dysfunction has also been
attributed to inactivation by abnormal ASL composition. Although initially attributed to inhibition by high
salt concentrations in CF ASL [44], differences in killing between CF and non-CF ASL remained even after
desalting procedures, but were rescued by adenoviral expression of CFTR [45]. The importance of pH
dysregulation in disease is emphasised by another study in which bicarbonate secretion through the CFTR
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was required for proper mucin secretion and normalisation of mucus with CF-like properties [46]. Other
innate defence mechanisms against microbial growth, including the generation of reactive oxygen and
nitrogen species, also appear lacking in CF. Specifically, loss of CFTR in the airway epithelium hinders
CFTR-dependent secretion of thiocyanate and its subsequent oxidation to hypothiocyanite, preventing
efficient bacterial killing [47]. Thiocyanate levels were found to correlate with better lung function in CF
patients, although levels were only slightly reduced in CF pigs and not different in CF patients and controls
[48]. Thiocyanate can also serve as an antioxidant, protecting against hypochlorite generation and excessive
inflammation [49]. Reduced glutathione (GSH), one of the primary antioxidants in the lung, also
undergoes transport into the airways by CFTR [3] and is consequently found to be decreased in BALF from
CF airways [50], but not sputum [51]. However, treatment with inhaled glutathione did not significantly
improve lung function or decrease exacerbation frequency over 6 months [52]. This was in contrast to an
earlier study that found significant improvement in FEV1 with treatment over 2 weeks [53], with decreases
in prostaglandin E2 and increases in CD4+ and CD8+ lymphocytes [54]. No reduction in oxidative stress
was observed in either trial. The inability of both endogenous and supplementary GSH to control oxidative
stress in the CF airways may result in excessive protein oxidation. This has been observed in the BALF of CF
patients where increased levels of oxidised proteins were found to correlate with increased airway neutrophil
counts and lower lung function [55], although neutrophil/myeloperoxidase-independent sources are also
likely to contribute. Oxidative damage may ultimately result in the loss of structure and function in proteins
important in host defence, such as surfactant proteins A and D (SP-A and D) [55–57]. Inactivation of
antimicrobials may also occur via a protease–antiprotease imbalance in the CF lung [58], in which NE and
other proteases have been shown to cleave a variety of targets, ranging from immunoglobulins to
complement, CXCR1 and SP-A and D [59]. Nitric oxide, another potent antimicrobial, also appears lacking
in CF. This may be due to decreased inducible nitric oxide synthase expression [60, 61], as well as increased
expression of the nitric oxide synthase inhibitor asymmetric dimethylarginine [62]. Low levels of nitric
oxide may also be attributed to infection by P. aeruginosa and nitric oxide reductase expression [63], which
it may utilise to feed into its cycle of anaerobic respiration.
The CF lung environment also affects cellular components of the immune system. Neutrophils, one of the
initial cellular responders to infection, have impeded motility due to the thickened CF airway mucus [64]
and pathogens such as Staphylococcus aureus and P. aeruginosa may effectively resist phagocytosis through
polysaccharide capsule or biofilm formation. This may be further affected by NE, which can directly damage
the airways and inhibit the capacity of neutrophils to eliminate bacteria [65]. Loss of CFTR has also been
implicated in directly causing cellular abnormalities. For example, CFTR is thought to play a role in the
suppression of inflammatory responses via nuclear factor (NF)-kB. This feeds into a hyperinflammatory
phenotype, as measured by mitogen-activated protein kinase and NF-kB activation, as well as inflammatory
cytokine production in airway epithelial cells and macrophages [66–71]. Increased inflammation was noted
even in the absence of observable infection [72, 73]. Neutrophils, a primary cell type in controlling acute
infection, are found to accumulate in great numbers in the CF lung. However, they are ultimately incapable
of successfully phagocytosing and clearing infection within the CF airway due to both intrinsic defects as
well as protease-mediated damage upon entrance into the airways [65]. Neutrophil activation may result in
protease, as well as oxidative-mediated damage that may actually worsen airway disease by inactivating
secreted antimicrobials and destroying airway structure [74, 75]. These abnormalities are further extended
to immune cells, which seem to favour a T-helper cell (Th)2/Th17 phenotype via production of the
cytokines IL-1b, 4, 5, 13 and 17 as opposed to a more protective Th1 phenotype against P. aeruginosa
[76–78]. It should be noted that it is possible that this skewing is at least due in part to the altered
inflammatory milieu created by innate immune dysfunction in CF. For a more comprehensive examination
of how the loss of CFTR affects immune function refer to HARTL et al. [75].
It has also been suggested that the CFTR may directly interact with pathogens, serving as a receptor for
intestinal epithelial uptake of Salmonella typhi [79] and airway epithelial uptake of P. aeruginosa [80, 81]
and Aspergillus fumigatus [82]. Inhibition of binding either through the expression of DF508-CFTR or by
pretreatment of the microorganism with purified CFTR peptide leads to increased bacterial survival, altered
inflammatory cytokine production and cell death. Interactions may also occur without direct interaction
with CFTR as in the case of phagosomal escape by Listeria monocytogenes. This process has been shown to be
dependent on CFTR channel activity with infection of DF508-CFTR expressing macrophages or chemical
inhibition of CFTR resulting in phagosomal retention and increased killing of bacteria [83]. Therefore, there
is evidence that supports both the localisation and function of CFTR as playing a role in antimicrobial
activity. However, the clinical consequences of CFTR localisation versus function have not been clearly
correlated with the effects of CFTR genotype on lung disease. This is due to interindividual variability,
effects of modifier genes and environmental considerations, which lead to significant variation in lung
function even amongst patients with the same CFTR genotype. As summarised in table 1, favourable growth
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conditions in combination with an ineffective host immune response create a rich, but competitive,
environment for a variety of microorganisms in the CF lung.
Infection in CF
Bacterial pathogens
CF airways appear normal at birth but soon become infected by a characteristic group of opportunistic
pathogens [42] that includes Haemophilus influenzae, S. aureus, P. aeruginosa, Stenotrophomonas maltophilia
and Achromobacter xylosoxidans. This characteristic infection profile tends to follow a distinct trend with
age: H. influenzae and S. aureus appear early in life (infants to children), whereas P. aeruginosa infection
occurs later in life (adolescence to adulthood). Once acquired, infections can become chronic and last for
years. Some CF pathogens have also been observed to be transmitted between individuals, including the
P. aeruginosa Liverpool and Australian Epidemic Strains (LES and AES, respectively) [54], Burkholderia
cepacia complex [84] and, most recently, Mycobacterium abscessus [85]. The acquisition of P. aeruginosa LES
and AES by patient-to-patient transmission was associated with clinical deterioration as measured by lung
function and body mass index (BMI) [86]. Co-infection with several of the primary CF pathogens may also
modify the course of a chronic CF lung infection, whereby their cohabitation in the CF lung occurs in both
mutually beneficial and detrimental capacities. As such, the prevalence of P. aeruginosa appears to correlate
inversely with the incidence of S. aureus infection in the CF population [87] and may reflect a mostly
antagonistic relationship between the two microorganisms. P. aeruginosa is known to secrete factors that
can inhibit the growth of competing S. aureus [88] or to use it as an iron source [89]. Conversely, S. aureus
has also been observed to take advantage of growth in proximity to P. aeruginosa whereby the secretion of
4-hydroxy-2-heptylquinoline-N-oxide helps protect S. aureus against aminoglycoside antibiotics and helps
select for small colony variants [90].
During the chronic colonisation of CF lungs, P. aeruginosa clones undergo phenotypic conversion. The
P. aeruginosa population diversifies in morphotype, motility, virulence, antimicrobial susceptibility and
production of adhesins, exopolysaccharides and secondary metabolites [91, 92]. Strains modulate the lipid
A structure of lipopolysaccharide (LPS), thereby affecting resistance to host cationic antimicrobial peptides
and induction of CXCL8 [93–96]. In addition to sensing LPS through Toll-like receptor (TLR)4, host
recognition of P. aeruginosa also occurs by recognition of flagellin through TLR5 [97] and has been shown
to be important for bacterial killing by alveolar macrophages [98]. Loss of motility/flagella is common in
chronically infecting strains [99]. Modulation of flagellin expression can occur in response to components
of CF mucus [100], such as NE [101], allowing for evasion of host recognition and phagocytosis [98, 99].
Flagellin induces the accumulation of myeloid-derived suppressor cells (MDSCs), which have been found to
accumulate in CF patients primarily infected with P. aeruginosa. MDSCs can contribute to the evasion of
adaptive immunity by suppressing T-cell responses [102]. Chronically infecting strains may also become
deficient in quorum sensing and acquire a persister phenotype [103–105]. High mutation rates were
observed in lineages that were defective in mismatch repair [106, 107]; however, if hypermutable strains did
not emerge in the patients’ lungs, mutation rates remained low [108]. Furthermore, novel adaptive or
TABLE 1 Summary of factors contributing to infection and pulmonary decline in cystic fibrosis
Lung environment
Defective cilia function
Increased mucus viscosity, hypoxia
Free nutrients: amino acids, iron
Damage to lung architecture: TGF-b, matrix metalloproteases, neutrophil elastase, oxidant/antioxidant
imbalance
Altered pH
Immune dysfunction
Defective and/or decreased antimicrobials: lysozyme, lactoferrin, b-defensins, pentraxin-3, thiocyanate,
nitric oxide, surfactant protein D
Th2 and Th17 responses
Ineffective cellular mediators: neutrophil accumulation and dysfunction
Microbial factors
Changes in virulence: lipid A structure, flagellin expression, loss of quorum sensing, acquisition of a
persistent phenotype and hypermutation
Biofilm formation
Polymicrobial interaction and secondary infection
Direct downregulation of antimicrobial pathways: vitamin D receptor downregulation by Aspergillus
TGF: transforming growth factor; Th: T-helper cell.
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pathogenic traits can be generated by few or even single mutations provided that predisposing mutational
events had occurred before in the clonal lineage [109]. Insight into the microevolution of P. aeruginosa in
CF lungs has mainly been gained by whole-genome sequencing of serial isolates [105, 110, 111]. Phenotypic
conversion is also often observed in chronic S. aureus infections. Typical traits are hypermutation via
insertional inactivation of mutS, biofilm formation and, most frequently, the emergence of small colony
variants, which possess higher survival during stationary and post-stationary phases, as well as in the
presence of P. aeruginosa and/or antimicrobials [112].
Although lung disease in CF was originally only attributed to specific microbes (S. aureus, and subsequently,
P. aeruginosa), it has since been established that standard culture methods do not adequately describe the
diversity of microbial populations present in the CF lung [113]. Previously overlooked pathogens are
increasingly being identified as significant contributors to CF lung disease including viruses, anaerobic
bacteria and fungal pathogens [114]. To aid in this, microbial identification by culture methodology has
been supplemented with molecular approaches such as sequencing of ribosomal RNA[113, 115] and
restriction fragment length polymorphism analysis [116] in order to obtain a more global view of the CF
infection status. Despite providing a more complete snapshot of airway microbial diversity, these methods
are also susceptible to false representation by the sample collection method employed. Samples collected
directly from lung tissue provide accurate and consistent results, whereas airway washings or expectorated
sputum may be prone to contamination by oropharyngeal populations [117]. For clinical purposes, it may
be very difficult to avoid contamination as minimisation of invasiveness takes precedence. However,
employment of bronchoalveolar lavage (BAL), when possible, could improve accuracy. Studies using
molecular approaches of microbial identification have found a statistical correlation with age and infection
by H. influenzae, S. maltophilia and P. aeruginosa [118], and relative stability of the CF microbiome, with
greater inter- rather than intra-individual variability. Increased disease severity has been positively
correlated with reduction in CF microbiome diversity [119–121], which has been attributed to long-term
antibiotic use, rather than patient age or lung function [120]. There is now ample evidence that a number of
viral, bacterial and fungal pathogens, beyond the dominant P. aeruginosa and S. aureus, can infect and adapt
to the CF lung and contribute to disease progression [87, 114].
Viral pathogens
Viral respiratory tract infections in healthy individuals are frequent and often resolve without significant
issue. However, they can lead to severe complications in patients, especially children, with chronic
respiratory diseases such as CF. Amongst respiratory viruses, rhinoviruses are the predominant viral
pathogens associated with pulmonary aggravations in CF, as they are detected in 20–60% of all virus-
associated CF exacerbations [122–124]. Elevated levels of inflammatory mediators and the subsequent
increases in inflammatory cells have been proposed to explain the increased morbidity caused by respiratory
viruses in CF [125, 126]. However, primary airway epithelial cells from healthy and CF patients, infected
with rhinoviruses, did not display an increased inflammatory response. There was instead a tendency to
lower cytokine levels associated with elevated cell death. This suggests that an elevated inflammatory
response upon infection does not explain the increased respiratory morbidity found in CF [127]. Moreover,
it has been reported that primary CF airway epithelial cells have an increased susceptibility to respiratory
viruses [126, 128]. These findings were confirmed in BAL samples of CF children where rhinovirus load was
elevated compared with control patients [129]. Besides their direct pneumopathological effects, respiratory
viruses also lead to an elevated susceptibility to bacterial infections through increased bacterial adhesion
(reviewed in [130]). For instance, respiratory syncytial virus has been reported to augment the adherence of
P. aeruginosa to CF airway epithelial cells [131] and there is evidence that rhinovirus increases H. influenzae,
S. aureus and S. pneumonia adhesion to primary healthy nasal epithelial cells [132].
Fungal pathogens
Fungal pathogens now have an increasingly appreciated role in CF lung disease. The most common ones are
Aspergillus and Candida species with A. fumigatus and C. albicans as the most prevalent filamentous and
yeast fungal species, respectively. Beyond these two prominent species, more exotic genera can also be found
in CF airway secretions, such as Penicillium, Alternaria or Scedosporium. Beyond CF, our understanding of
the complex age, ethnicity and medication dependent colonisation of the lung with fungi is an area that is
starting to evolve. Studies from this field provide the first evidence that even healthy airways are not sterile
and contain distinct fungi, termed the ‘‘pulmonary mycobiome’’. The kinetics, dynamics and disease
relevance of the pulmonary mycobiome, however, are poorly understood [133–135].
Despite the increasing detection rate of fungi in CF airways, their pathogenic relevance in the longitudinal
course of CF lung disease remains poorly understood and remains, therefore, an ongoing matter of debate.
The contribution of A. fumigatus to the allergic disease entity termed allergic bronchopulmonary
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aspergillosis (ABPA) [136], one form of allergic bronchopulmonary mycosis [137], is appreciated. However,
unresolved and controversial questions in the field include: 1) the disease relevance of chronic colonisation/
infection with A. fumigatus without the clinical phenotype of ABPA [138], and 2) the relevance of chronic
infection with C. albicans [139]. While environmental exposure to fungi is common to CF and non-CF
individuals, the impaired mucociliary clearance in CF lungs favours chronic fungal colonisation. As a
consequence, the pulmonary immune system is in long-term and intimate contact with fungal allergens that
are exposed by the fungus after spore swelling and germination [140]. This host–pathogen interaction is the
immunological prerequisite for the establishment of an allergic reaction. Despite the correlation between
exposure to Aspergillus spores and the development of ABPA, several studies provide strong evidence that
ABPA is primarily the result of a dysregulated host immune response to Aspergillus antigens [76, 141, 142].
The mechanisms by which CF patients become sensitised to the airway microenvironment remain largely
elusive, but previous concepts allow speculation that dendritic cells and Th2-associated chemokines and
cytokines, such as CCL17/thymus and activation-regulated chemokine and thymic stromal lymphopoeitin,
in CF airways play a critical role in this process [142, 143]. Fungi in the airways are mainly sensed by
alveolar macrophages, epithelial cells and neutrophils through two distinct pattern recognition receptor
(PRR) families: C-type lectin receptors (CLRs), with Dectin-1 as the prototypic fungal CLR PRR, and TLRs
[144], with TLR2, TLR4 and TLR6 playing the major roles [145–148]. Engagement of Dectin-1 by whole
fungi through the ‘‘phagocytic synapse’’ [149] or fungal components initiates antifungal effector activities,
such as phagocytosis [150]. Besides cellular surface receptors, fungi are recognised by humoral PRR,
such as SP-D or pentraxin-3, which can be degraded and rendered dysfunctional in the CF airway
microenvironment [151, 152].
Regarding adaptive immunity, the Th17 response is essentially involved in anti-fungal host defense [153],
with Th17-released IL-17A protein binding fungal cells and causing nutrient starvation [154]. However,
over-activation of Th17 responses drives hyperinflammation [155]. This has potential therapeutic
implications, as indoleamine 2,3-dioxygenase, a key enzyme of tryptophan metabolism, is involved in Th17
hyperinflammation in CF [78] and tryptophan catabolites (kynurenines) could be therapeutically useful to
regulate and dampen hyperinflammation [156, 157]. Vitamin D is an important regulator of innate
immunity. The vitamin D pathway has been proposed to be involved in the Th2-driven immunopathogen-
esis of ABPA in CF patients, where vitamin D deficiency has been identified as an important risk factor.
Indeed, it was found that CD4+ T-cells and dendritic cells pulsed with Aspergillus extract and subsequently
treated with vitamin D produced less IL-5 and IL-13 [142]. Conversely, Aspergillus derived gliotoxin was
shown to impair vitamin D receptor expression and induce the Th2 cytokines IL-5 and IL-13 in bronchial
epithelial cells. The effects of gliotoxin were dominant over the effects of vitamin D supplementation on
IL-5 and IL-13 secretion. Therefore, supplementation with vitamin D for disease alleviation may require
concurrent fungal eradication [158]. Overall, many factors have been found to contribute to the permissive
environment of the CF lungs, allowing for infection and persistence by a variety of microorganisms (fig. 1).
The inflammatory consequences of dysfunctional immune mechanisms in CF: the
example of modifier genes
Genome wide association and linkage studies have allowed the identification of genes that appear to play a
significant role in modulating disease severity in CF on a population scale (i.e. modifier genes).
Interestingly, many of the genes identified have been shown to play direct antimicrobial roles or are
important in the regulation of immune responses. This could emphasise the critical role of inflammatory
interactions between host and pathogen in worsening lung disease. One of the first identified, MBL2
(mannose-binding lectin (protein C) 2, soluble), recognises N-acetylglucosamine on bacterial cell walls and
activates complement for both the direct lysis and recruitment of effector phagocytes to the site of infection.
MBL2-deficiency is quite prevalent in the human population [159, 160] and is suspected to predispose
individuals to severe respiratory tract infections. Although association of MBL2 polymorphisms with
disease severity has been inconsistent in CF populations, meta-analysis of existing studies has found that
patients deficient in MBL2 have been associated with worse lung function, earlier acquisition of
P. aeruginosa, and increased incidence of death or need for lung transplantation [161]. Furthermore, disease
severity was significantly augmented in individuals with MBL2-deficiency who also produced high amounts
of transforming growth factor (TGF)-b [162]. Although not directly involved in sensing or combating
microorganisms, TGF-b is secreted upon infection and plays an important role, along with the
inflammatory cytokines IL-1b and IL-6, in the development of a Th17 inflammatory phenotype which may
be responsible for driving excess inflammatory responses in CF epithelia [163, 164] and for increased
permissibility to infection by P. aeruginosa [78]. TGF-b also has direct functions in tissue remodelling and
may further contribute to worsening lung disease by mediating progressive fibrotic changes to the lung
architecture [78] and has itself been firmly established as a modifier gene in CF [165].
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Besides modifier genes, biomarker proteins have been shown to predict the course of CF lung disease.
Importantly, proteases are already present in early CF lung disease and have recently been demonstrated to
predict the course of CF bronchiectasis [166]. However, clinical trials with inhalational a1-antitrypsin
did not show efficacy in improving lung function, but did decrease neutrophilic inflammation markers
[59, 167]. Further studies, are warranted, but may require a more efficient drug delivery system to ensure
adequate lung deposition of a1-antitrypsin. A genetic association with better disease outcomes was also
observed in patients possessing polymorphisms for interferon-related developmental regulator 1 (IFRD1)
[168, 169]. IFRD1 is important in neutrophil differentiation and controls inflammation through generation
of reactive oxygen species and NF-kB p65 translocation. IFRD1-deficient neutrophils were found to be less
effective at killing microorganisms. IFRD1 is overexpressed in CF blood neutrophils as compared to
controls, although CF airway neutrophils tended to have lower IFRD1 expression, which may be due to the
high levels of CXCL8 and CXCL2 typically found in the CF airways [169]. Associations were also detected
a)
Pseudomonas aeruginosa
Rhinovirus
Germination and
antigen exposure
Periciliary layer:
Reduced volume
Cilia dysfunction
Conidial uptake
without CFTR
Th2/Th17 cytokines
VDR expression
(gliotoxin-mediated)
Mucous layer: acidic, thickened, hypoxic
CEACAM
Cell death
Adhesion molecules
and bacterial adherence
Hypermutability
Lipid A modification AMP resistance
Hyperinflammation
Flagellin regulation Loss of motility
MDSC induction
TLR5
Modulation of chronic inflammatory
Important in phagocytosis/bacterial
killing by alveolar macrophages
CF airway epithelial cell
responses: CXCL8 production
TLR4
Antibiotic resistance
b) c)
Aspergillus
fumigatus
conidia
FIGURE 1 Host–pathogen interactions in cystic fibrosis (CF). This figure illustrates a few of the various interactions between bacterial, viral and fungal pathogens
and the CF host. a) Chronically infecting strains of Pseudomonas aeruginosa frequently acquire hypermutable phenotypes through mismatch repair deficiency,
encouraging antibiotic resistance and adapted virulence. Inflammatory responses are modulated through changes in lipid A structure and flagellin expression.
This provides resistance to host antimicrobial peptides (AMP) and alters CXCL8 production through Toll-like receptor (TLR)4. Loss of motility/changes in
flagellin expression can occur in order to evade recognition by TLR5 and phagocytosis by alveolar macrophages. The presence of flagellin can also induce
development of myeloid-derived suppressor cells (MDSCs) leading to suppression of T-cell responses. b) Rhinoviral infection may increase expression of cellular
adhesion molecules, such as carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), and enhance attachment of bacterial pathogens to host cells.
c) Decreased uptake of Aspergillus fumigatus conidia by cystic fibrosis transmembrane conductance regulator (CFTR)-deficient epithelial cells results in reduced
clearance and increased cell death. Germination from spore to hyphal form results in increased inflammatory responses. Bronchial epithelial cells induce T-cell-
mediated T-helper cell (Th)2 and Th17 responses complicit in allergic bronchopulmonary aspergillosis. This may be further enhanced by A. fumigatus mediated
downregulation of the vitamin D receptor (VDR) and increased interleukin (IL)-5/IL-13 production by gliotoxin.
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between the inflammatory genes IL-1b, TLR9, TNF-a, CD95, STAT3 and TNFR in a CF twin/sibling cohort
with extreme disease phenotypes. These genes were analysed for their ability to impact Cl- transport across
nasal and intestinal epithelia, providing evidence that inflammatory genes do indeed modify the basic defect
in CF [170]. Another gene found to modify the basic defect in CF was TLR5, an extracellular sensor for
flagellin, which corroborated findings showing reduced TLR5 expression and responsiveness was associated
with an improved zBMI score in adults but not children with CF [171].
In addition to candidate gene studies, exome sequencing has been successfully applied to identify a genetic
modifier of the age-dependent risk of becoming colonised with P. aeruginosa in CF. The presence of a
missense variant in DCTN4 (encodes dynactin-4 protein) was significantly associated with an early age of
onset for first and chronic infection with P. aeruginosa, earlier age of onset for first mucoid P. aeruginosa
culture and decreased time to conversion from P. aeruginosa positive culture to mucoid P. aeruginosa
positive culture [172]. These findings were determined by exome sequencing of individuals with extreme
phenotypes of either very early or very late onset of P. aeruginosa infection and subsequent genotyping of an
independent non-stratified replication cohort.
Infections in CF and non-CF lung disease
Many other non-CF pulmonary diseases also exhibit chronic opportunistic polymicrobial infection,
including diffuse pan bronchiolitis, primary ciliary dyskinesia and chronic obstructive pulmonary disease
(COPD). This indicates that infection may be a result of broad dysfunction of pulmonary antimicrobial
defences in these diseases. These diseases also possess similarity in the profile of dominant infecting
microorganisms (H. influenzae, P. aeruginosa and S. aureus), which may be attributed to the ubiquity and
adaptability of these bacteria to persist within the lung microenvironment. Importantly, the nature and
patterns of infection do differ between diseases and may reflect subtleties in defective host defence
mechanisms or airway conditions. For example, although patients with COPD can be colonised by
P. aeruginosa, infections are usually not chronic and are easily treatable [173]. Analysis of the lung
microbiome in COPD has also indicated that its composition does indeed change with severity although its
makeup is different to that in CF [174]. Inflammatory biomarkers in sputum in general show similarities
between CF and COPD and negatively correlate with lung function in both [175]. Additionally, both CF
and COPD are characterised by increased numbers of airway neutrophils, antiprotease–protease imbalance
and oxidative stress [173], and are modified in disease severity by TGF-b [176, 177]. Despite differences in
disease origin and infecting pathogens, this may indicate the involvement of similar pathological processes
in these conditions. Further mechanistic definition of which specific pathogens are restricted in certain
airway diseases, but not others, may help shed light on the aspects of host defence that confer effective
resistance against specific pathogens.
Conclusions and future directions
Having summarised and discussed the complex relationship between host and pathogens in CF lung disease,
the following questions remain open to be addressed in the future. How can the CF host response be
specifically targeted in order to dampen excessive inflammation without impairing protective immune
responses? How do CF airway pathogens regulate each other? Should antibiotic strategies aim to render CF
lungs sterile or are certain microbes protective? And if so, is this protective effect age-, CFTR genotype-,
gene modifier- and/or medication-dependent? What is the pathogenic contribution of fungi and viruses in
the longitudinal course of CF lung disease? Which modifier genes could be helpful in subclassifying CF
patients and predicting the response to bacterial infections and disease outcomes?
The combined power of cellular studies, murine models, the CF pig and, most importantly, studies with CF
patients will be required to address these complex issues. These different approaches have their individual
pitfalls and strengths: murine models of CF do not produce CF lung disease similar to that in humans [178]
and substantial differences exist between the murine and human lung architecture. By contrast, pig and
ferret models develop lung disease that is more similar to humans [178], but are more expensive.
Consequently, translational and multi-methodological research consortiums should pave the way in this
research field, with the ultimate goal of improving the length and quality of life of people living with CF.
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